Kyntra Bio, Inc
Price
FilingsNewest: 8-K, Director or officer changeOct 1 →Insiders1 insider bought $53,602 in 3 open-market buys. No sales.→HoldersArmistice Capital 9.9%Vanguard 4.0%BlackRock 2.1%→Financing →PeersClosest companies: INCY, BCRX, ZYME→
From the filings
Figures
- Revenue
- $4.6Mlast 12 months
- Net income
- $183.2Mlast 12 months
- Operating cash flow
- −$21.4Mlast 12 months
- Cash and equivalents
- $50.6Mat the last balance sheet
- Shares outstanding
- 4.0M shareson issue